Eli Lilly is making waves in the corporate debt market with a $6.75 billion multi-tranche bond sale that includes a rare 40-year note: an unusual move for a pharmaceutical company. Most corporate bonds mature in five to 30 years. Analysts say the deal, which went to market last month, furnishes the drugmaker cheap, long-term capital that could fund strategic growth. Similar 40-year issuances have been seen only sparingly, such as Alphabet’s May issuance, which marked its return to the bond